Cord Blood News 9.19 May 18, 2017 | |
| |
TOP STORYInvestigators evaluated the potency of highly active natural killer (NK) cells derived from human CD34+ hematopoietic stem and progenitor cells to infiltrate and mediate the killing of human ovarian cancer spheroids using an in vivo-like model system and mouse xenograft model. [Oncoimmunology] Full Article | |
| |
PUBLICATIONS(Ranked by impact factor of the journal)Scientists investigated the possible role of menaquinone-4 (MK-4), an isoform of the menaquinones family, in the modulation of osteogenesis. They used a model of human amniotic fluid mesenchymal stem cells (hAFMSCs) cultured both in two-dimensional (2D) and three-dimensional (3D) in vitro culture systems. Their results demonstrated that MK-4 supported the hAFMSCs aggregate formation and increased the osteogenic functions. [J Tissue Eng Regen Med] Abstract Researchers compared phagocytic activity, infection induced apoptosis, expression of B-cell lymphoma-2 family proteins, production of reactive oxygen species, cytokine production and T-cell suppression of neonatal granulocytic-MDSCs after infection with E. coli to neonatal autologous mature polymorphonuclear leukocytes. [Eur J Immunol] Abstract The authors report the transplant outcomes of 27 patients with hematologic cancers who received one cord blood (CB) unit ex vivo expanded with mesenchymal precursor cells in addition to an unmanipulated CB unit after reduced intensity conditioning (RIC). The results in this group were compared with 51 historical controls who received two unmanipulated CB units. [Biol Blood Marrow Transplant] Abstract Investigators analyzed survival outcomes of 30 heavily pretreated multiple myeloma patients who received haploidentical hematopoietic cell transplantation (haplo-HCT) with post-transplant cyclophosphamide as graft-versus-host-disease (GvHD) prophylaxis. No differences were observed between peripheral blood and bone marrow graft in terms of engraftment, GvHD or progression of disease incidence. [Biol Blood Marrow Transplant] Abstract The authors investigated the restorative effect on neonatal intraventricular hemorrhage (IVH) by umbilical cord-derived mesenchymal stromal cells (UC-MSCs) cultured in serum-free medium (RM medium) for clinical application. Their results suggest UC-MSCs attenuate neonatal IVH by protecting gliosis and apoptosis of the injured brain, and intravenous injection of UC-MSCs cultured in RM medium may be feasible for neonatal IVH in clinic. [Neuroscience] Abstract Researchers evaluated the myogenic differentiation property of human chorion-derived mesenchymal stem cells in comparison with umbilical cord blood-derived mesenchymal stem cells in the presence of 5-azacytidine. [Tissue Cell] Abstract | |
| |
REVIEWSBone marrow aspirates, mobilized peripheral blood and umbilical cord blood have developed as graft sources of hematopoietic stem and progenitor cells (HSPC) for stem cell transplantation and other cellular therapeutics. Individualized techniques are necessary to enhance graft HSPC yields and cell quality from each graft source. The authors elucidate the past, present and potential future approaches to HSPC graft optimization. [Biol Blood Marrow Transplant] Abstract Cord Blood as a Potential Therapeutic for Amyotrophic Lateral Sclerosis Researchers discuss the composition, in vitro and in vivo differentiation of human umbilical cord blood (hUCB) cells, and the advantages of cord blood as a source of transplant cells are discussed. They provide a brief history of hUCB in treatment of an amyotrophic Lateral Sclerosis (ALS) animal model and the feasibility of these cells in therapy for ALS patients. [Expert Opin Biol Ther] Abstract Visit our reviews page to see a complete list of reviews in the cord blood research field. | |
| |
SCIENCE NEWSGlycoMimetics, Inc. announced the release of abstracts containing new data from the ongoing Phase II clinical trial of its product candidate GMI-1271, an E-selectin antagonist, in patients with acute myeloid leukemia (AML). [Press release from GlycoMimetics, Inc. discussing research to be presented at the American Society of Clinical Oncology (ASCO) Annual Meeting, Chicago, and the European Hematology Association (EHA) Annual Meeting, Madrid] Press Release | |
| |
INDUSTRY NEWSGlycoMimetics, Inc. announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation for treatment of adult relapsed/refractory acute myeloid leukemia (AML) to the company’s drug candidate GMI-1271, an E-selectin antagonist currently being evaluated in the Phase II portion of a Phase I/II clinical trial in patients with AML. [GlycoMimetics, Inc.] Press Release Terumo BCT announced that the first patient has been enrolled in the Mirasol Platelets in Plasma clinical trial using the Mirasol® PRT System. The U.S. trial is designed to evaluate the clinical effectiveness of Mirasol-treated apheresis Platelets in Plasma versus standard apheresis Platelets in Plasma. [Terumo BCT] Press Release | |
| |
POLICY NEWSAs Ebola Outbreak Grows, Question of Using Vaccine Becomes More Urgent As health officials and aid workers head to a remote corner of the Democratic Republic of the Congo to respond to an outbreak of Ebola virus disease, a key question remains: Will the government authorize the use of a promising experimental vaccine? The vaccine had stunning results in a clinical trial in Guinea in 2015, but it has yet to be licensed for broad use. [Science Insider] Editorial Lawmakers Decry Trump Plan to Slash NIH 2018 Budget Lawmakers from both sides of the aisle in the U.S. House of Representatives voiced their displeasure with the Trump administration’s proposed $5.8 billion cut to the budget of the National Institutes of Health in Bethesda, Maryland. [Science Insider] Editorial China’s Belt and Road Infrastructure Plan Also Includes Science China’s plan to make massive investments in land and sea links with global trading partners also includes a little noticed commitment to support science and engineering, including the creation of dozens of new laboratories. [ScienceInsider] Editorial Trump Officials Act to Tilt Federal Science Boards toward Industry Critics say that changes to advisory groups at the Environmental Protection Agency and Department of Interior could restrict or paralyze them. [Nature News] Editorial
| |
EVENTSNEW AACR-NCI-EORTC Molecular Targets & Cancer Therapeutics Visit our events page to see a complete list of events in the community.
| |
JOB OPPORTUNITIESNEW Postdoctoral Fellow – Molecular Hematology (University of Gothenburg, Institute of Biomedicine) NEW Research Associate – Stromal Cell-Based Immunotherapies (Orbsen Therapeutics Limited) MD/PhD Student – Malignant Hematology (Leiden University Medical Center) Postdoctoral Position – Acute Myeloid Leukemia (LMU Munich) Postdoctoral Position – Mesenchymal Stem Cell (Longboats Explorers Inc.) Senior Research Scientist – Immunotherapy (Anthony Nolan Research Institute) Full Member Faculty – Hematopoietic Cell Transplant Program (Fred Hutchinson Cancer Research Center) Assistant Member Faculty – Platinum/Immunotherapy (Fred Hutchinson Cancer Research Center) Recruit Top Talent: Reach potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.
| |
Have we missed an important article or publication in Cord Blood News? Click here to submit! Comments or suggestions? Submit your feedback here. | |
|
Home Cord Blood News Volume 9.19 | May 18 2017